Patents by Inventor Eric Stawiski

Eric Stawiski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACE2 RECEPTOR POLYMORPHISMS AND VARYING SUSCEPTIBILITY TO SARS-COV-2, METHODS FOR DIAGNOSIS AND TREATMENT
    Publication number: 20230203466
    Abstract: Human ACE2 variants are provided including methods of use thereof. The ACE2 receptor variants may be used for diagnosis and treatment of COVID-19.
    Type: Application
    Filed: April 5, 2021
    Publication date: June 29, 2023
    Inventors: Somasekar Seshagiri, Eric Stawiski, Kushai Suryamohan, Ravi Gupta, Jagath Reddy Junutula
  • MIT BIOMARKERS AND METHODS USING THE SAME
    Publication number: 20200138944
    Abstract: Provided are therapies related to the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: October 9, 2019
    Publication date: May 7, 2020
    Applicant: Genentech, Inc.
    Inventors: Steffen Durinck, Bijay Jaiswal, Zora Modrusan, Somasekar Seshagiri, Eric Stawiski, Na Zhang
  • MIT BIOMARKERS AND METHODS USING THE SAME
    Publication number: 20180250394
    Abstract: Provided are therapies related to the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: December 8, 2016
    Publication date: September 6, 2018
    Applicant: Genentech, Inc.
    Inventors: Steffen Durinck, Bijay Jaiswal, Zora Modrusan, Somasekar Seshagiri, Eric Stawiski, Na Zhang
  • Methods and Compositions for Determining Altered Susceptibility of HIV-1 to Protease Inhibitor Treatment
    Publication number: 20100227313
    Abstract: This invention relates to methods for determining altered susceptibility of HIV-I viruses to protease inhibitors (PIs) based on the viral genotypes. The methods generally comprise detecting, in a gene encoding protease and/or gag of the HIV-I, the presence of mutations correlated with altered susceptibility to amprenavir and/or darunavir.
    Type: Application
    Filed: February 25, 2008
    Publication date: September 9, 2010
    Inventors: Neil T. Parkin, Colombe Chappey, Eric Stawiski